Black, Hispanic HCV patients more likely to fail DAA therapy

Black and Hispanic patients with hepatitis C virus infection were less likely to achieve sustained virologic response with direct-acting antiviral agents compared with white patients within the U.S. Veterans Affairs health care system, according to recent study results. Further, black patients with HCV genotype 1 infection who were treated with Harvoni (ledipasvir/sofosbuvir, Gilead) monotherapy were significantly less likely to achieve SVR compared with